QIAGEN powered by
Welcome to QIAGEN
Digital Insights
LabCorp uses QCI and HGMD to improve identification and interpretation of genetic variants within inherited diseases.
Read Press Release
Software and Services for actionable insights
Previous
Next

40+

integrated databases 

33,000+

disease classes covered

20M+

curated findings

5,000+

new data findings/day

1,000,000+

patient tests analyzed

Expert curated genomic and clinical knowledge,
software and services for actionable insights

Accelerated Decisions

Real time access and analysis of over 40 genomic and clinical databases covering over 33,000 diseases.

Deeper Insights

Advanced analysis, workflow and interpretation software accessing genomic and clinical knowledge from over 20 million references.

Better Outcomes

Evidence based research, services and advanced software for better decisions.

35,000+

publications cite QIAGEN’s bioinformatics products as part of their research and clinical insights

Products from Bench to Bedside

Sample to Insight
DNA Panel Testing

Targeted NGS panels and optimized analysis and interpretation tools. 

Research Bioinformatics Services

Discovery Bioinformatics Services is a reliable and convenient way to extend your in-house resources with expertise and perfectly tailored bioinformatics services that ensure high-quality results.

Pharmaceutical Development Services

Enabling pharma companies to develop biomarker diagnostics and targeted therapies using real-world insights from oncology patient genomic data.

Clinical Analysis & Interpretation Services

Helping clinical testing laboratories leverage the benefits of automation and expert support to improve test turnaround times, enhance clinical reporting capabilities and scale for future growth.

Uncover critical and timely insights

QIAGEN maintains the world’s largest, expert-curated knowledgebase of up-to-date evidence for discovery research, clinical test interpretation and pharmaceutical development. 

Case Study 1

Interpretation of gene expression data to tackle inflammatory bowel disease

Case Study 2

In Germany, scientists tackle cancer cohorts with Sample to Insight QIAGEN tools.

Case Study 3

Mount Sinai's novel biomarker predicts treatment outcome in ovarian cancer